Jazz Pharmaceuticals Improvement Grants: Improving Guideline-Concordant Glioma Molecular Testing and Treatment in the United States

Jazz Pharmaceuticals Improvement Grants: Improving Guideline-Concordant Glioma Molecular Testing and Treatment in the United States is a quality improvement funding opportunity developed through a collaboration between Jazz Pharmaceuticals and EveryGrant powered by Conquer Cancer, the ASCO Foundation. Conquer Cancer serves as the primary administrator for application review and evaluation, while Jazz Pharmaceuticals will provide grant funding directly to selected recipients. The initiative responds to gaps in the real-world use of molecular testing and molecular classification for gliomas in the United States, particularly in community oncology settings. The program recognizes that molecular features are essential to accurate glioma diagnosis, grading, prognostication, and determination of patient eligibility for guideline-concordant standards of care, targeted therapy, and clinical trials. The RFP seeks projects that implement strategies to support and measurably improve equitable delivery of guideline-concordant molecular testing and care for pediatric and adult glioma patients in the United States. Proposals should apply quality improvement standards to assess current adherence to treatment guidelines, identify guideline-discordant care, and implement measures that improve testing and treatment. Projects are expected to address equitable access, involve relevant stakeholders and the patient community where appropriate, and be sustainable, scalable, and transferable to other settings. Applicants are encouraged to improve knowledge of and access to precision medicine, testing efficiency in community settings, collaboration and referral pathways between centers of excellence and community practices, use of clinical data to identify care gaps, and multidisciplinary approaches to glioma care. The RFP also expects projects to disseminate their processes and outcomes to the broader oncology community. Eligible applicants include U.S. healthcare delivery systems and academic and community oncology delivery networks, with applications from community cancer care providers specifically encouraged. Proposals should represent multidisciplinary teams delivering care to glioma patients. Collaboration among healthcare centers and organizations, particularly community care providers, is encouraged, as is collaboration with patient advocates, patient advocacy organizations, or other groups capable of representing the perspectives of glioma patients. Awards will be made only to eligible organizations and institutions; individual healthcare professionals cannot receive awards directly. Projects should include evidence of challenges in the care delivery system and involve the affected patient population and cross-functional care delivery team. The grant is not intended to fund creation of new care delivery roles or clinical research projects evaluating the efficacy or safety of therapeutic or diagnostic agents. The total available budget for the RFP is $1,000,000 USD. Individual projects requesting up to $125,000 USD will be considered, and total project costs, including overhead, may not exceed $125,000 over a 24-month period. Indirect costs may be included in the requested budget but are subject to Jazz Pharmaceuticals approval if an application is selected. The final grant amount for an individual project will depend on the review panel's evaluation of the proposal and associated costs and will be stated in the grant agreement. No cost-share or matching requirement is stated in the RFP. Projects are expected to be sustainable beyond the grant funding period and scalable to broader application. The anticipated project period is January 2027 through December 2028. Applications must be completed in English and submitted online through the EveryGrant application portal at everygrant.smapply.us. Applicants must create an account before submission, and applications sent by mail, email, or fax are not accepted. Required application elements include an eligibility form and confirmation of the specific glioma program, Principal Investigator information and an NIH Biosketch or SciENcv, project title and summary or abstract, applicable IRB information, and a quality improvement proposal uploaded as a PDF of no more than 10 pages. The proposal addresses goals and objectives, assessment of need with baseline data or a plan to obtain it, target audience, project design and methods, evaluation and outcomes, dissemination, anticipated project timeline, and organization and partner details. Applicants must also provide a one-page summary of prior quality improvement experience, complete the portal budget form, submit an institutional letter of support, and complete required applicant organization information including legal name and address, organizational classification, EIN, and an authorized signing official signature page. Collaboration letters and additional information are optional. Jazz Pharmaceuticals and Conquer Cancer, in collaboration with the Society for Neuro-Oncology, will convene a Scientific Review Committee serving as the Expert Review Panel. Subject matter experts will conduct independent and confidential peer review of in-scope proposals. Jazz Pharmaceuticals will participate as a non-voting member, and funding allocations will follow the panel's recommendations. Review criteria include the impact and innovation of the proposed project, approach and feasibility, scalability, transferability and sustainability, organizational capacity and leadership, and adherence to the requirements of the RFP. The RFP was issued September 1, 2026, and full proposals are due October 15, 2026. Review of full proposals is scheduled for November 15, 2026, with notification anticipated by the end of November 2026. Grants will be distributed after execution of a complete grant agreement. The source does not identify the opportunity as recurring. Questions about EveryGrant may be directed to EveryGrant@conquer.org.

Use quantitative baseline data or a clearly described plan to establish the care gap; design measurable evidence-based interventions aligned with guideline-concordant molecular testing and care; address equitable access and involve affected patients and the cross-functional care team; demonstrate feasibility, organizational capacity, sustainability, scalability, and transferability; plan broad dissemination of outcomes; strengthen collaboration between community practices and centers of excellence where applicable; do not propose creation of care-delivery roles or clinical research evaluating therapeutic or diagnostic efficacy or safety